Stem Cell Therapies in Peripheral Vascular Diseases — Current Status

Diana Opincariu¹,², András Mester¹,², Imre Benedek¹,², István Benedek¹,³

¹ University of Medicine and Pharmacy, Tîrgu Mureș, Romania
² Center of Advanced Research in Multimodality Cardiac Imaging, Cardio Med Medical Center, Tîrgu Mureș, Romania
³ Clinic of Hematology and Bone Marrow Transplantation Unit, Tîrgu Mureș, Romania

ABSTRACT
Peripheral artery diseases include all arterial diseases with the exception of coronary and aortic involvement, more specifically diseases of the extracranial carotids, upper limb arteries, mesenteric and renal vessels, and last but not least, lower limb arteries. Mononuclear stem cells, harvested from various sites (bone marrow, peripheral blood, mesenchymal cells, adipose-derived stem cells) have been studied as a treatment option for alleviating symptoms in peripheral artery disease, as potential stimulators for therapeutic angiogenesis, thus improving vascularization of the ischemic tissue. The aim of this manuscript was to review current medical literature on a novel treatment method — cell therapy, in patients with various peripheral vascular diseases, including carotid, renal, mesenteric artery disease, thromboangiitis obliterans, as well as upper and lower limb artery disease.

Keywords: stem cells, peripheral vascular diseases, endothelial precursor cells, therapeutic angiogenesis

INTRODUCTION
According to the 2017 guideline of the European Society of Cardiology on the management of peripheral artery disease (PAD), the term “PAD” includes all arterial diseases with the exception of coronary and aortic involvement, more specifically diseases of the extracranial carotids, upper limb arteries, mesenteric and renal vessels, and last but not least, lower limb arteries. Peripheral arterial disorders affect approximately 40 million inhabitants in Europe, leading to increased healthcare costs, as well as high morbidity and mortality rates and impaired health-related quality of life. The most frequently cited cause for PADs with various locations is atherosclerosis, therefore the risk increases with age and exposure to classical cardiovascular risk factors including dyslipidemia, diabetes, chronic tobacco use, arterial hypertension, obesity, and newer factors such as enhanced systemic inflammation, hyperhomocysteinemia and various genotypes. Ongoing research is required for developing new therapeutic measures for subjects that present no indication for either inter-

Journal of Interdisciplinary Medicine 2017;2(S4):12-19
DOI: 10.1515/jim-2017-0093
vential or surgical revascularization — the so called “no-option” patients.

The aim of this manuscript was to review current medical literature on a novel treatment method — cell therapy, in patients with various peripheral vascular diseases, including carotid, renal, mesenteric artery disease, thromboangiitis obliterans, as well as upper and lower limb artery disease.

**PERIPHERAL ARTERY DISEASES — MORE THAN WORDS CAN SAY**

As previously mentioned, PADs are located in several vascular sites, leading to devastating repercussions that comprise multiple aspects of the healthcare system from an economical point of view, as well as individual quality of life, morbidities and mortality rates.

Patients with PAD present increased risk for cardiovascular adverse events irrespective of the site of the lesions. Subjects with carotid artery disease have been shown to have increased risk of acute cerebrovascular events, acute myocardial infarction, and cardiac death. The prevalence of asymptomatic carotid stenoses of >50% is 4.2%, showing an increasing rate with age in Europe, while in the United States, the rate of moderate to severe carotid artery disease was found to be 3.9%.

Upper extremity ischemic disease is less common than lower limb PAD, accounting for less than 5% of all cases of limb ischemia. Atherosclerotic disease is rarely the sole culprit of critical ischemia of the upper limbs; more often, Buerger’s thromboangiitis obliterans or systemic sclerosis are the responsible causes. Subclavian stenosis is frequently caused by atherosclerotic plaques, with an increasing prevalence from 2% in the general population, to 9% in subjects with lower limb PAD. The clinical presentation of subclavian artery disease includes various symptoms, from hand claudication to several manifestations of the subclavian steal phenomenon, with cerebral hypoperfusion, or, in subjects with coronary bypass grafting and axillo-bifemoral bypass, it could lead to chest pain or lower limb claudication respectively.

Thromboangiitis obliterans, or Buerger’s disease is a non-atherosclerotic segmental inflammatory disease characterized by the presence of thrombosis in the small and medium arterial vasculature, affecting mainly young subjects with a positive history of chronic tobacco use, with frequent distal upper limb involvement, but it can also affect the lower limbs, leading to severe ischemic pain, gangrene of the extremities, and culminating with limb amputation.

Mesenteric artery disease is often undiagnosed in clinical practice, and it causes approximately 5% of all acute intestinal ischemic events. The coeliac trunk is more often affected than the superior mesenteric artery, as it was shown by a study on a population undergoing cardiac catheterization, in which the prevalence of mesenteric artery disease was 14%, out of which 11% was located in the coeliac trunk.

Atherosclerotic renal artery disease has been shown to affect 6.8% of subjects in the Cardiovascular Health Study, regardless of gender or age, although it affected significantly more male patients than females (9.1% versus 5.5% respectively, p = 0.05), and its incidence was independently associated with increasing age, LDL cholesterol levels, and increasing systolic blood pressure. Another study on 866 patients undergoing simultaneous coronary and renal artery angiography, found significant atherosclerotic renal artery stenosis in 39.8% of cases, from which 22.3% were with bilateral involvement, while age, female gender, hypertension, left anterior descendant and circumflex artery stenosis of more than 50% were found to be independent predictors for renal artery stenosis.

Approximately 202 million subjects suffer from lower limb PAD around the globe, showing an increasing incidence with age. The gender distribution varies between lower and middle-income states, where women are more affected than men, and higher income countries, where there is a net male predominance in the non-elderly population. Critical limb ischemia, the end stage of chronic lower limb PAD, is present in 500–1000 new cases per million, with increasing incidence among diabetic patients, and is not only associated with high morbidity and mortality rates, but also with high risk of limb amputation.

The annual amputation rate above and below the knee is between 120 to 500 in every million lower limb PAD subjects. The death rate related directly to lower limb PAD is 3.5 per 100,000 individuals, but most patients will succumb to complications related to coronary artery disease or stroke, as PAD is a marker for systemic atherosclerotic involvement.

**THERAPEUTIC USE OF STEM CELLS IN PERIPHERAL ARTERY DISEASES**

Bone marrow-derived stem cells (BMSC) have been studied as a therapeutic option for alleviating symptoms in PAD as potential stimulators for therapeutic angiogenesis, thus improving vascularization of the ischemic tissue and enhancing both perfusion and woundhealing. Cell therapies with either BMSC or progenitor cells derived from
Peripheral blood may offer ongoing sources of growth factors and structural tissue components for vessel regeneration or neoformation.29

Angiogenesis refers to the development of preexisting capillary endothelial tubules as a response to tissue ischemia, being mediated by hypoxia-induced release of vascular growth factors and related cytokines.30 Arteriogenesis is the development of the collateral vascular network by an increase in the diameter of the preexistent collateral arterioles, which will act as a sustaining vascular network that compensates the function of the occluded vessels.31–33 The physiological stimulation of arteriogenesis occurs in conditions of increased shear stress, leading to a mechanical increase in vessel diameter, followed by the activation of adhesion molecules and cytokine release that will attract circulating monocytes, which are actually bone-marrow derived cells. Monocytes activate matrix proteases that will create the spatial conditions needed for vessel growth, and within 3–4 weeks from the occlusion of a large artery, the collateral arteries will be able to provide a proper blood flow to the affected tissue.34,35 Several studies have sought to find the role of the bone marrow derived monocytes in the arteriogenesis process, and the findings suggest that the stem cells stimulate artery development not by incorporating into the vessel wall, but by promoting cytokine release, which offer paracrine stimulation of vascular growth.34,36

Circulating endothelial progenitor cells (EPC) were first described by Asahara et al.,37 and were shown to originate from bone marrow-derived monocytes that are present in the vicinity of the collateral vessels.38 Another observation that sustains the promoter role of BMSC in arterial collateralization present in PAD, was that the number of circulating monocytoic endothelial progenitor cells was lower if risk factors such as diabetes, tobacco use, dyslipidemia, or old age were present. These are the same risk factors associated with failed collateral development and with the severity of PAD.28,39–43

These observations have led to the birth of a new concept: therapeutic stimulation of angiogenesis by stem cell infusion. Cell therapy aims to stimulate physiological arteriogenesis, by using an increased number of precursor cells that will provide the required cytokines for an accelerated arteriogenesis.44 Several studies on cell therapies for improvement of tissue perfusion have been carried out, with either bone-marrow derived monocytes or peripheral blood mononuclear cells that express surface markers that identify human EPC, more specifically CD133, CD34, KDR (kinase insert domain receptor), and VEGF receptor 2.45–48

## STEM CELL THERAPIES IN VARIOUS TYPES OF PAD

### Carotid artery disease and stroke

Although cell therapies in stroke patients do no induce collateral vessel formation, there are several preclinical and clinical studies that have researched the effect of intravenous and intra-arterial stem cell injection for improving the neurological deficits of acute ischemic stroke patients.49–53 Preclinical studies have found that the implantation of bone marrow mononuclear cells, which include, among other types, hematopoietic and mesenchymal stem cells, may reduce the size of cerebral infarction and improve the functional outcomes by producing various cytokines and growth factors.54–57 These observations have set the base for multiple clinical studies in which stem cells were injected intracerebrally, intravenously, or intra-arterially in patients with acute cerebral ischemia, and all have found potential benefits in cell therapies for stroke patients.58,59 However, several questions should be answered by larger randomized controlled clinical trials, regarding the timing (acute or chronic phase of brain ischemia),60,61 the type of cell (bone marrow-derived, peripheral blood-derived, fetal cells),49 route of delivery (intracerebral, intra-arterial, intravenous),62–65 and infusion rates (larger vessels mean increased infusion rates and vice versa),66,67 and last but not least, those regarding the safety of the procedure.58,61,68,69

### Upper limb ischemia

While there is an increasing number of studies that sustain the clinical benefits of cell therapies in coronary artery disease and lower limb ischemia,70–75 there are scarce data on their role in upper limb ischemia, which is rarer, but if present, is associated with significantly worse outcomes and increased mortality rates.76,77 There is a whole body of evidence on the beneficial effects of different cell therapies in lower limb PAD,78 but there are few data on the effect of angiogenesis stimulation in upper limb ischemia. However, there are reports of several cases with critical ischemia of the upper limb that have benefited from BMSC as an angiogenic inducer.79,80 Camerota et al. have reported the case of a 63-year-old diabetic male with bilateral upper limb digital gangrene caused by atherosclerosis. The patient had received several injections at the level of the forearms and hands, in which bone marrow-derived tissue repair cells were delivered with the purpose of improving tissue perfusion. The 1-year follow-up showed a significant improvement in clinical perfusion sings (wound heal-
ing, no need for analgesics, complete resolution of pain, and improved quality of life), as well as a better perfusion, objectively seen with plethysmography. Nevskaya et al. reported 2 cases with ischemic digital wounds caused by systemic sclerosis, in which the patients had received mononuclear cells derived from the peripheral blood and from the bone marrow. The results showed increased skin perfusion, wound healing, and improved blood flow in the brachial artery in both cases. A study on 7 subjects with hand ischemia (rest pain, non-healing ischemic ulcers), either caused by thromboangiitis or an autoimmune disease, found that at 6 months after the injection of a mixture of CD34+ and CD 133+ cells, all patients presented improved digital-brachial pressure index, lower score on the visual analogue scale for pain, and ulcer healing. These reports and pilot studies may be suggesting that autologous bone marrow-derived cells could become a safe method for therapeutic angiogenesis in patients with critical hand ischemia as well; however, further research on larger patient populations is required.

**Thromboangiitis obliterans**

The role of cell therapies in improving ischemic signs and symptoms of patients with Buerger’s disease has been studied in various clinical trials. Subjects with Buerger’s disease are not suitable candidates for revascularization procedures in the presence of critical limb ischemia due to the frequent involvement of distal low-caliber arteries. Lee et al. have performed intramuscular implantation of whole bone marrow stem cells in 90 limbs from 67 subjects with symptomatic Buerger’s disease and observed significant clinical and angiographical improvement, as well as a decrease in amputation rates. Kim et al. carried out a study on 27 patients with lower limb thromboangiitis who were not suitable for surgical or interventional revascularization, in which they implanted isolated EPCs from the bone marrow in the tibial bone, in association with subcutaneous injection of granulocyte colony-stimulating factor (GCS-F). During a mean follow-up of 19.1 months, from 17 limbs with non-healing ulcers, 13 were healed, and 14 patients presented visible collateral growth on the control angiography, while only 6 showed no collaterals. They also found a significant increase in the number of EPCs in the peripheral blood after GCS-F administration. Motukuru et al. conducted a 6-month follow-up study on non-reconstructible Buerger’s disease patients who underwent BMSC transplantation into the calf muscles of the affected limb. After 6 months, patients presented significant improvement in ulcer healing, increased ankle-brachial index (p < 0.01), and transcutaneous oximetry values (p <0.01). Similar results were found by Durdu et al., who injected autologous BMSC after erythrocyte depletion, in various regions with ischemic lesions (gastrocnemius muscle, intermetatarsal region, feet dorsum, or forearm) in 28 patients with Buerger’s disease, which were followed up for 16.6 ± 7.8 months. They observed that 83% of patients presented ulcer healing, all patients presented relief of rest pain and no need for analgesics, while in 78.5% of cases, collateral vessels had formed after 6 months from BMSC implantation. The results of all these studies suggest the positive effects of angiogenesis stimulation with endothelial precursor cells in patients with Buerger’s disease, in which established therapies such as smoking cessation or vasodilator therapies have failed, and who, due to the involvement of small-caliber vessels, are not candidates for surgical or interventional revascularization procedures. Thus, there is supporting data regarding the initiation of larger clinical trials for the assessment of cell therapies in subjects with thromboangiitis obliterans.

**Mesenteric artery ischemia and reperfusion injury**

Mesenteric ischemia is rarely caused by atherosclerosis (5% of intestinal ischemia cases), being frequently undiagnosed. Intestinal ischemia is more often caused by necrotizing enterocolitis, trauma, septic shock, strangulated hernias and volvulus, or cardiac surgery, and it presents a very high risk of death. No clinical research on cell therapies in mesenteric atherosclerosis have been conducted, but there are several preclinical studies on the effect of stem cells in intestinal ischemic and reperfusion injuries. Jiang et al. investigated the effect of BMSC in intestinal ischemia on 100 rats in which the superior mesenteric artery was clamped for 45 minutes, followed by the injection of BMSC in the submucosa of the small intestine, followed by reperfusion. Their results showed a significant reduction and an accelerated recovery of the intestinal barrier dysfunction in the BMSC group. Jensen et al. performed a similar study on a mouse population, in which human adipose-derived stromal cells were infused into the peritoneum, after 60 minutes of clamping the superior mesenteric artery. The results showed a higher 7-day survival, increased mesenteric perfusion, lower inflammatory status, and preserved intestinal architecture for adipose-derived stromal cell-treated mice. Stem cells have been shown to provide benefits in the case of intestinal ischemia and reperfusion injuries in preclinical settings, albeit no data is available on cell therapies in atherosclerotic mesenteric artery stenosis. These early
observations could represent a stepping stone for future research on the currently developing applications of stem cell therapies.

Renal ischemia

Atherosclerosis of the renal arteries is one of the major causes of chronic renal disease, which implies the gradual reduction of the glomerular filtration rate (GFR) due to ischemic loss of renal parenchyma, which will eventually lead to 6–27% of end-stage renal insufficiencies.94,95 Restoring the impaired blood flow to the kidney in renal artery stenosis does not always succeed in reestablishing kidney function and improving the GFR; the identification of other restorative therapeutic measures is of utmost importance.96 Mesenchymal stem cell therapies for various types of kidney injuries have been the subject of research in many preclinical and clinical studies, most of them focusing on acute kidney injury.97–100 The repair mechanism of mesenchymal stem cells (MSC) includes cytokine release and MSC differentiation into renal cells; MSC can be implanted intravenously, intra-arterially, or within the kidney parenchyma.101

Ischemic chronic kidney disease caused by renal artery stenosis is characterized by glomerular fibrosis and decreased number of microvessels, with secondary triggering of the renin angiotensin aldosterone cascade, with subsequent vasoconstriction, inflammation and fibrosis.102,103 Others have shown that the implantation of endothelial progenitor cells has led to tissue repair, decreased inflammation and fibrosis.102,103 Others have shown that the implantation of MSC in the renal artery, with or without concomitant revascularization, led to an important improvement of kidney function, as well as a decrease in oxidative stress, inflammation, and fibrosis.104,105

Saad et al. conducted a clinical study in which 14 subjects with atherosclerotic renovascular disease received an intra-arterial infusion of MSC in association to the standard medical treatment. These subjects were matched by 14 patients who had received medical treatment only. During the 3-month follow-up, the MSC group presented increased cortical perfusion, the renal blood flow rose in the stenotic kidney from 151.8 mL/min to 185.5 mL/min (p = 0.01), and kidney hypoxia decreased from 12.1% to 6.8% (p = 0.04), as assessed by blood oxygen level-dependent MRI.106

The current preclinical and smaller clinical studies on cell therapies in renal artery stenosis and its subsequent damage show that there is hope in restoring renal function in these patients, in which percutaneous revascularization alone is most often not a viable solution for repairing neither the kidney lesions, nor their local and systemic cardiovascular impact; however, further human studies are required for the clinical implementation of the procedure.

Lower limb ischemia

The rationale for cell therapies in lower limb artery disease is to promote collateralization and angiogenesis, and therefore to improve tissue perfusion and wound healing, and prevent amputations.107 Cell therapies in lower limb ischemia are generally reserved for patients who do not present indication for interventional or surgical revascularization, or in whom these methods have failed, more specifically, for no-option critical limb ischemic patients.108,109 There is extensive clinical research on the topic of therapeutic angiogenesis in lower limb PAD, showing a clear benefit in various types of precursor cells, either autologous (endothelial precursor cells, BMSC, peripheral blood stem cells, mesenchymal or adipose-derived stem cells) or allogeneic, the latter presenting the disadvantage of possible immune rejection.110

Several clinical trials have been conducted on bone-marrow derived mononuclear cells implantation in ischemic lower limbs. The TACT trial (Therapeutic Angiogenesis by Cell Transplantation), one of the first clinical studies on the matter, included a pilot study in which 22 patients with lower limb PAD had received BMSC in one leg and saline solution in the other, and a randomized clinical trial in which other 22 patients with ischemic lower limbs received BMSC in one leg and peripheral blood-derived precursor cells in the other. The results showed that in both studies there were significant improvements in transcutaneous oxygen pressure, pain-free walking time, and ankle brachial index, but the results were better in the patients treated with bone marrow-derived stem cells.111 Other trials have also confirmed the efficacy of cell therapies in promoting vessel collateralization, symptom improvement, and wound healing in lower limb critical ischemia.112–116 A meta-analysis published by Rigato et al. included 67 studies (randomized and non-randomized clinical trials, and non-controlled studies), on a total number of 2,352 patients with intractable lower limb PAD or critical limb ischemia, and the primary outcome of the studies was limb amputation.112 From the analysis of randomized clinical trials, their results showed a 37% reduction on amputation rates after cell therapies, as well as a 59% improvement of wound healing, significantly lower rest pain and higher
ankle-brachial index and tissue oxygen pressure. They also found that intramuscular implantation of cells is more effective compared to the intra-arterial approach, and that bone marrow-derived mononuclear cells are better than peripheral blood cells or mesenchymal stem cells in obtaining successful results. Also, they found no important adverse reactions to cell therapies.\textsuperscript{112}

Therapeutic angiogenesis in no-option critical lower limb ischemia is a promising novel treatment method that offers hope of escaping amputation, an improvement in the overall quality of life, pain-free time, and higher values for indicators of tissue perfusion (ankle-brachial index, tissue oxygen perfusion). The extensive preclinical and clinical data on autologous stem cell implantation, either in the muscle or in the artery, or a combination of the two, has the possibility to change the outcome of intractable critical limb ischemia.

**THE FUTURE OF STEM CELL THERAPIES IN PAD**

Well-planned randomized controlled studies are still needed to assess the long-term effects of stem cell implantation for different peripheral artery diseases. The use of programmed allogeneic progenitor cells in patients who present autologous stem cell exhaustion could present a new branch in the therapeutic angiogenesis tree, and the recruitment of stem cells from healthy, HLA-matched donors may provide alternative cellular sources that are less affected by chronic associated diseases.\textsuperscript{117–119} Moreover, genetic therapies based on in vivo gene transferring for inducing angio- and arteriogenesis in combination with stem cell transplantation could better the outcome of patients in which all the applied therapeutic measure have failed.\textsuperscript{107,130}

**CONCLUSIONS**

There are still multiple untouched territories in stem cell research, including their use in therapeutic angiogenesis for various peripheral vascular diseases. However, their efficacy in enhancing tissue oxygenation, angio- and arteriogenesis in the ischemic segment, as well as accelerating wound healing and improving the functional features of the affected organ, has been proved by various researchers in all peripheral artery diseases (carotid, renal, mesenteric, upper and lower limb). Despite the increasing body of data from preclinical studies for renal or mesenteric artery disease, as well as more frequent clinical trials for lower limb ischemia, there is a long road ahead until stem cell implantation will be listed in the therapeutic guideline recommendations for such disorders, requiring further multicenter randomized clinical trials on larger populations.

**CONFLICT OF INTEREST**

Nothing to declare.

**REFERENCES**


---


